Phage therapy efficacy: a review of the last 10 years of preclinical studies

dc.commentsCEB53535por
dc.contributor.authorMelo, Luís Daniel Rodriguespor
dc.contributor.authorOliveira, Hugo Alexandre Mendespor
dc.contributor.authorPires, Diana Priscila Pensopor
dc.contributor.authorDabrowska, Krystynapor
dc.contributor.authorAzeredo, Joanapor
dc.date.accessioned2020-04-29T18:02:24Z
dc.date.available2020-04-29T18:02:24Z
dc.date.issued2020-02-24
dc.date.updated2020-04-18T09:55:31Z
dc.description.abstractDue to the rise of multidrug-resistant infections in humans, phage therapy is gaining renewed attention in Western medicine. Despite the increasing number of publications focussed on the isolation, characterization and in vitro performance of different phages, there is still a lack of concise pre-clinical information to guide the application of phage therapy in clinical practice. Nevertheless, over the last decade, efforts have been made to conduct more detailed studies of the in vivo efficacy of phages. Here, we review the most relevant in vivo studies performed in the last decade covering phage efficacy in both preclinical and clinical trials. We compare different routes of administration, dosage effect and different animal models of distinct types of infections. Moreover, insights into case studies and results from clinical trials are presented. Challenges and limitations of phage use as evidenced by the current state of research are also discussed in order to improve both the trustworthiness and success of the implementation of phage therapy.por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion
dc.description.sponsorshipThis study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469/2013 unit, COMPETE 2020 [POCI-01-0145-FEDER-006684] and Projects PTDC/SAU-PUB/29182/2017 [POCI-01-0145-FEDER-029182] and PTDC/CVTCVT/29628/2017 [POCI-01-0145-FEDER-029628]. This work was also supported by BioTecNorte operation [NORTE-01- 0145-FEDER-000004] funded by the European Regional Development Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. DPP was supported by a FCT grant [SFRH/BPD/116187/2016]. KD is the recipient of the National Science Centre in Poland grant [UMO-2018/29/B/NZ6/01659]. The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.por
dc.distributioninternationalpor
dc.identifier.citationMelo, Luís D. R.; Oliveira, Hugo; Pires, Diana P.; Dabrowska, Krystyna; Azeredo, Joana, Phage therapy efficacy: a review of the last 10 years of preclinical studies. Critical Reviews in Microbiology, 46(1), 78-99, 2020por
dc.identifier.doi10.1080/1040841X.2020.1729695por
dc.identifier.eissn1549-7828por
dc.identifier.issn1040-841Xpor
dc.identifier.pmid32091280por
dc.identifier.urihttps://hdl.handle.net/1822/65136
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherTaylor and Francispor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147337/PTpor
dc.relationPTDC/SAU-PUB/29182/2017por
dc.relationPTDC/CVTCVT/29628/2017por
dc.relationSFRH/BPD/116187/2016por
dc.relation.publisherversionhttp://informahealthcare.com/journal/mbypor
dc.rightsopenAccesspor
dc.subjectPhage therapypor
dc.subjectpreclinicalpor
dc.subjectrespiratory tract infectionspor
dc.subjectgastrointestinal tract infectionspor
dc.subjectbacteraemiapor
dc.subject.wosScience & Technologypor
dc.titlePhage therapy efficacy: a review of the last 10 years of preclinical studiespor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationEndPage99por
oaire.citationIssue1por
oaire.citationStartPage78por
oaire.citationVolume46por
sdum.journalCritical Reviews in Microbiologypor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_53535_1.pdf
Tamanho:
2.21 MB
Formato:
Adobe Portable Document Format